Holdings of Virtus Biotech Clinical Trials Etf
ETFis Series Trust I · Original filing · Compare with another fund · Report an error
- Net assets
- 46.4M $ including 46.3M $ in equities, 99.8 %
- Positions
- 131 in 9 countries
- Top ten
- 11.8 % of net assets
- Filed on
- Jul 31, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | First Tracks Biotherapeutics Inc | 17,620 | 776K $ | 1.67 % |
| 2 | MBX BIOSCIENCES INC | 8,754 | 577.2K $ | 1.24 % |
| 3 | AtaiBeckley Inc | 79,289 | 569.3K $ | 1.23 % |
| 4 | Monopar Therapeutics Inc | 5,200 | 563.4K $ | 1.21 % |
| 5 | Definium Therapeutics Inc | 12,558 | 546.5K $ | 1.18 % |
| 6 | Xencor Inc | 25,208 | 509.5K $ | 1.10 % |
| 7 | ZENAS BIOPHARMA INC | 15,697 | 493.5K $ | 1.06 % |
| 8 | uniQure NV | 11,273 | 491.8K $ | 1.06 % |
| 9 | Apogee Therapeutics Inc | 3,519 | 471.9K $ | 1.02 % |
| 10 | VOR BIOPHARMA INC | 21,644 | 457.8K $ | 0.99 % |
| 11 | REGENXBIO Inc | 46,670 | 452.2K $ | 0.97 % |
| 12 | LB Pharmaceuticals Inc | 10,936 | 438.3K $ | 0.94 % |
| 13 | DAMORA THERAPEUTICS INC | 14,957 | 433.6K $ | 0.93 % |
| 14 | AMYLYX PHARMACEUTICALS INC | 21,303 | 432.7K $ | 0.93 % |
| 15 | DYNE THERAPEUTICS INC | 17,087 | 430.3K $ | 0.93 % |
| 16 | ORUKA THERAPEUTICS INC | 4,447 | 429.2K $ | 0.93 % |
| 17 | Nurix Therapeutics Inc | 18,337 | 425.6K $ | 0.92 % |
| 18 | ORIC Pharmaceuticals Inc | 37,585 | 416.1K $ | 0.90 % |
| 19 | GH RESEARCH PLC | 14,716 | 413.1K $ | 0.89 % |
| 20 | Sionna Therapeutics Inc | 8,653 | 407.8K $ | 0.88 % |
| 21 | Dianthus Therapeutics Inc | 3,787 | 404.9K $ | 0.87 % |
| 22 | Erasca Inc | 22,122 | 401.5K $ | 0.87 % |
| 23 | JADE BIOSCIENCES INC | 20,261 | 400.2K $ | 0.86 % |
| 24 | SELLAS Life Sciences Group Inc | 39,695 | 397.3K $ | 0.86 % |
| 25 | PALVELLA THERAPEUTICS INC | 2,856 | 397.1K $ | 0.86 % |
| 26 | Relay Therapeutics Inc | 20,989 | 395.2K $ | 0.85 % |
| 27 | Replimune Group Inc | 35,001 | 392K $ | 0.85 % |
| 28 | Alto Neuroscience Inc | 14,476 | 391.9K $ | 0.84 % |
| 29 | ADLAI NORTYE LTD | 30,117 | 391.5K $ | 0.84 % |
| 30 | Bicara Therapeutics Inc | 14,331 | 388.4K $ | 0.84 % |
| 31 | Immunome Inc | 16,911 | 384.9K $ | 0.83 % |
| 32 | AVALO THERAPEUTICS INC | 21,058 | 384.3K $ | 0.83 % |
| 33 | MeiraGTx Holdings plc | 32,410 | 382.1K $ | 0.82 % |
| 34 | Ideaya Biosciences Inc | 10,725 | 380.7K $ | 0.82 % |
| 35 | SpyGlass Pharma Inc | 16,855 | 379.7K $ | 0.82 % |
| 36 | Kodiak Sciences Inc | 9,125 | 379.4K $ | 0.82 % |
| 37 | REVOLUTION MEDICINES INC | 2,020 | 378.8K $ | 0.82 % |
| 38 | Celldex Therapeutics Inc | 9,940 | 378.3K $ | 0.82 % |
| 39 | Spyre Therapeutics Inc | 3,847 | 378.3K $ | 0.82 % |
| 40 | Cullinan Therapeutics Inc | 22,687 | 374.3K $ | 0.81 % |
| 41 | LEXICON PHARMACEUTICALS INC | 161,882 | 373.9K $ | 0.81 % |
| 42 | Xenon Pharmaceuticals Inc | 5,966 | 373.9K $ | 0.81 % |
| 43 | KYMERA THERAPEUTICS INC | 3,605 | 372.8K $ | 0.80 % |
| 44 | Biohaven Ltd | 27,554 | 372K $ | 0.80 % |
| 45 | CG ONCOLOGY INC | 5,218 | 371.5K $ | 0.80 % |
| 46 | Nektar Therapeutics | 5,234 | 369.9K $ | 0.80 % |
| 47 | Enliven Therapeutics Inc | 6,738 | 369.3K $ | 0.80 % |
| 48 | ARCUS BIOSCIENCES INC | 13,060 | 368.2K $ | 0.79 % |
| 49 | TYRA BIOSCIENCES INC | 11,516 | 367.1K $ | 0.79 % |
| 50 | Rezolute Inc | 77,705 | 366.8K $ | 0.79 % |
| 51 | COGENT BIOSCIENCES INC | 9,390 | 365.6K $ | 0.79 % |
| 52 | ALUMIS INC | 12,870 | 363.6K $ | 0.78 % |
| 53 | Candel Therapeutics Inc | 36,310 | 363.5K $ | 0.78 % |
| 54 | Sana Biotechnology Inc | 115,976 | 363K $ | 0.78 % |
| 55 | ACHIEVE LIFE SCIENCES INC | 56,308 | 361.5K $ | 0.78 % |
| 56 | Olema Pharmaceuticals Inc | 31,490 | 360.6K $ | 0.78 % |
| 57 | VIRIDIAN THERAPEUTICS INC | 19,010 | 359.7K $ | 0.78 % |
| 58 | Praxis Precision Medicines Inc | 1,166 | 358.9K $ | 0.77 % |
| 59 | 4D Molecular Therapeutics Inc | 35,199 | 358.3K $ | 0.77 % |
| 60 | IMMUNOVANT INC | 9,245 | 357K $ | 0.77 % |
| 61 | BELITE BIO INC | 2,250 | 356.9K $ | 0.77 % |
| 62 | VAXCYTE INC | 6,549 | 354.2K $ | 0.76 % |
| 63 | Disc Medicine Inc | 4,571 | 352K $ | 0.76 % |
| 64 | Rocket Pharmaceuticals Inc | 113,024 | 351.5K $ | 0.76 % |
| 65 | Generate Biomedicines Inc | 25,106 | 351.5K $ | 0.76 % |
| 66 | Neurogene Inc | 10,681 | 351.3K $ | 0.76 % |
| 67 | Solid Biosciences Inc | 43,531 | 350.9K $ | 0.76 % |
| 68 | Maze Therapeutics Inc | 12,924 | 347.9K $ | 0.75 % |
| 69 | STRUCTURE THERAPEUTICS INC | 7,240 | 347.8K $ | 0.75 % |
| 70 | Janux Therapeutics Inc | 22,923 | 347.7K $ | 0.75 % |
| 71 | Corvus Pharmaceuticals Inc | 26,054 | 345.5K $ | 0.74 % |
| 72 | Design Therapeutics Inc | 28,333 | 345.1K $ | 0.74 % |
| 73 | Viking Therapeutics Inc | 10,811 | 343.1K $ | 0.74 % |
| 74 | Edgewise Therapeutics Inc | 8,925 | 343K $ | 0.74 % |
| 75 | Aura Biosciences Inc | 48,490 | 339.9K $ | 0.73 % |
| 76 | ASSEMBLY BIOSCIENCES INC | 13,537 | 339.9K $ | 0.73 % |
| 77 | VERADERMICS INC | 3,235 | 339.7K $ | 0.73 % |
| 78 | ABCELLERA BIOLOGICS INC | 59,315 | 338.7K $ | 0.73 % |
| 79 | Altimmune Inc | 119,086 | 338.2K $ | 0.73 % |
| 80 | Annexon Inc | 65,989 | 336.2K $ | 0.72 % |
| 81 | Mineralys Therapeutics Inc | 13,159 | 335.8K $ | 0.72 % |
| 82 | Scholar Rock Holding Corp | 7,035 | 332.7K $ | 0.72 % |
| 83 | Rapport Therapeutics Inc | 8,094 | 331.7K $ | 0.72 % |
| 84 | Pharvaris NV | 10,118 | 330K $ | 0.71 % |
| 85 | Arvinas Inc | 41,004 | 329.3K $ | 0.71 % |
| 86 | PRIME MEDICINE INC | 112,004 | 327.1K $ | 0.71 % |
| 87 | BridgeBio Oncology Therapeutics Inc | 40,107 | 324.5K $ | 0.70 % |
| 88 | Climb Bio Inc | 27,171 | 323.3K $ | 0.70 % |
| 89 | SAVARA INC | 59,090 | 322.6K $ | 0.70 % |
| 90 | Upstream Bio Inc | 50,952 | 321.5K $ | 0.69 % |
| 91 | CYTOMX THERAPEUTICS INC | 103,259 | 320.1K $ | 0.69 % |
| 92 | Taysha Gene Therapies Inc | 54,433 | 319K $ | 0.69 % |
| 93 | Oculis Holding AG | 28,027 | 317K $ | 0.68 % |
| 94 | Arbutus Biopharma Corp | 72,962 | 316.7K $ | 0.68 % |
| 95 | AKTIS ONCOLOGY INC | 14,173 | 312.8K $ | 0.67 % |
| 96 | Vir Biotechnology Inc | 36,099 | 312.6K $ | 0.67 % |
| 97 | Allogene Therapeutics Inc | 163,586 | 307.5K $ | 0.66 % |
| 98 | MoonLake Immunotherapeutics | 16,630 | 306.7K $ | 0.66 % |
| 99 | Immix Biopharma Inc | 36,782 | 306K $ | 0.66 % |
| 100 | Prothena Corp PLC | 37,674 | 305.9K $ | 0.66 % |
Sector breakdown
- Unattributed 100.0 %
Titelia assigns each company to a sector, one by one. The unassigned share stays visible, under "Unattributed".
Currency breakdown
- USD 100.0 %
Each line is counted in its quoted currency, as the fund declares it.
Country breakdown
- United States 86.5 %
- Cayman Islands 4.0 %
- Netherlands 3.0 %
- Ireland 1.6 %
- Canada 1.5 %
- United Kingdom 1.3 %
- British Virgin Islands 0.8 %
- Switzerland 0.7 %
- Singapore 0.6 %
Shares are computed on the fund's equities only.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 113 | 40.1M $ | 86.48 % |
| 2 | Cayman Islands | 5 | 1.9M $ | 4.04 % |
| 3 | Netherlands | 4 | 1.4M $ | 3.01 % |
| 4 | Ireland | 2 | 719K $ | 1.55 % |
| 5 | Canada | 2 | 712.6K $ | 1.54 % |
| 6 | United Kingdom | 2 | 588.3K $ | 1.27 % |
| 7 | British Virgin Islands | 1 | 372K $ | 0.80 % |
| 8 | Switzerland | 1 | 317K $ | 0.68 % |
| 9 | Singapore | 1 | 291.8K $ | 0.63 % |
Cite this page
Titelia. "Holdings of Virtus Biotech Clinical Trials Etf". https://titelia.com/en/funds/S000047353